藍帆醫療:擬發行不超2億元疫情防控相關公司債券
格隆匯2月11日丨藍帆醫療(002382.SZ)公佈,自新型冠狀病毒感染的肺炎疫情發生以來,截至2020年2月11日,公司已響應和支持1200餘家機構與個人總計超過2億支手套的捐贈和購買需求。
為了保障疫情期間公司防控產品持續穩定生產、加大供應,進一步支持疫情防控工作,公司擬申請面向合格投資者公開發行不超過人民幣2億元(含2億元)的疫情防控相關公司債券,發行方式為一次發行或分期發行,期限為不超過3年(含3年),為固定利率債券。
扣除發行費用後,本次發行疫情防控相關公司債券的募集資金將用於補充公司與防控新型冠狀病毒肺炎的醫療健康防護物資的生產與採購相關的流動資金及適用的法律法規允許的其他用途。具體募集資金用途提請股東大會授權董事會或董事會授權人士根據公司資金需求情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.